INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 157 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is 2.78 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,342,463 | -16.6% | 72,409 | -50.2% | 0.00% | – |
Q2 2023 | $1,608,720 | +2.1% | 145,454 | +24.0% | 0.00% | – |
Q1 2023 | $1,575,849 | +84.6% | 117,338 | +70.1% | 0.00% | – |
Q4 2022 | $853,443 | -34.2% | 68,993 | -25.8% | 0.00% | – |
Q3 2022 | $1,297,000 | +30.9% | 92,992 | +29.5% | 0.00% | – |
Q2 2022 | $991,000 | -31.7% | 71,821 | -19.5% | 0.00% | – |
Q1 2022 | $1,450,000 | -2.9% | 89,188 | -2.8% | 0.00% | – |
Q4 2021 | $1,494,000 | -36.0% | 91,780 | -41.6% | 0.00% | -100.0% |
Q3 2021 | $2,334,000 | +61.4% | 157,212 | +117.2% | 0.00% | – |
Q2 2021 | $1,446,000 | +61.6% | 72,380 | +86.8% | 0.00% | – |
Q1 2021 | $895,000 | -49.9% | 38,743 | -46.4% | 0.00% | – |
Q4 2020 | $1,787,000 | -8.5% | 72,320 | +53.6% | 0.00% | -100.0% |
Q3 2020 | $1,953,000 | -47.3% | 47,074 | -39.2% | 0.00% | 0.0% |
Q2 2020 | $3,709,000 | -26.6% | 77,408 | -3.6% | 0.00% | -50.0% |
Q1 2020 | $5,054,000 | -64.4% | 80,258 | -29.9% | 0.00% | -50.0% |
Q4 2019 | $14,187,000 | +58.8% | 114,488 | -15.0% | 0.00% | +33.3% |
Q3 2019 | $8,936,000 | +17.3% | 134,671 | +40.6% | 0.00% | +50.0% |
Q2 2019 | $7,620,000 | +0.7% | 95,755 | +41.6% | 0.00% | 0.0% |
Q1 2019 | $7,564,000 | +19.7% | 67,625 | +7.8% | 0.00% | 0.0% |
Q4 2018 | $6,321,000 | -12.3% | 62,719 | +10.0% | 0.00% | 0.0% |
Q3 2018 | $7,206,000 | +24.6% | 57,033 | -17.2% | 0.00% | 0.0% |
Q2 2018 | $5,783,000 | +28.2% | 68,910 | -6.0% | 0.00% | +100.0% |
Q1 2018 | $4,510,000 | +16.3% | 73,311 | +10.5% | 0.00% | 0.0% |
Q4 2017 | $3,877,000 | -28.9% | 66,360 | -29.3% | 0.00% | -50.0% |
Q3 2017 | $5,451,000 | -32.6% | 93,910 | +40.6% | 0.00% | -33.3% |
Q2 2017 | $8,088,000 | +12.5% | 66,804 | +5.0% | 0.00% | +50.0% |
Q1 2017 | $7,192,000 | -0.9% | 63,604 | -4.8% | 0.00% | -33.3% |
Q4 2016 | $7,258,000 | -4.1% | 66,798 | +45.3% | 0.00% | 0.0% |
Q3 2016 | $7,565,000 | +12.2% | 45,967 | -2.7% | 0.00% | 0.0% |
Q2 2016 | $6,742,000 | +29.2% | 47,250 | +16.4% | 0.00% | +50.0% |
Q1 2016 | $5,217,000 | -8.9% | 40,606 | +6.0% | 0.00% | 0.0% |
Q4 2015 | $5,724,000 | +4.3% | 38,324 | +15.8% | 0.00% | 0.0% |
Q3 2015 | $5,488,000 | -87.3% | 33,085 | -81.6% | 0.00% | -88.2% |
Q2 2015 | $43,326,000 | +338.7% | 179,719 | +413.2% | 0.02% | +750.0% |
Q1 2015 | $9,876,000 | +972.3% | 35,022 | +493.4% | 0.00% | – |
Q4 2014 | $921,000 | -57.0% | 5,902 | -34.8% | 0.00% | -100.0% |
Q3 2014 | $2,142,000 | -56.3% | 9,049 | -56.3% | 0.00% | -50.0% |
Q2 2014 | $4,905,000 | -21.1% | 20,722 | +9.9% | 0.00% | -33.3% |
Q1 2014 | $6,216,000 | – | 18,849 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Samsara BioCapital, LLC | 640,688 | $14,787,000 | 2.73% |
DeepCurrents Investment Group LLC | 416,800 | $9,620,000 | 0.33% |
DUALITY ADVISERS, LP | 105,668 | $2,439,000 | 0.21% |
EULAV Asset Management | 335,000 | $7,732,000 | 0.21% |
Virtus ETF Advisers LLC | 19,375 | $447,000 | 0.19% |
Hennion & Walsh Asset Management, Inc. | 135,214 | $3,121,000 | 0.19% |
PDT Partners, LLC | 110,592 | $2,552,000 | 0.18% |
KETTLE HILL CAPITAL MANAGEMENT, LLC | 70,256 | $1,622,000 | 0.16% |
ALTRINSIC GLOBAL ADVISORS LLC | 168,800 | $3,896,000 | 0.12% |
WOODWARD DIVERSIFIED CAPITAL, LLC | 8,939 | $206,000 | 0.12% |